Pluristem Launches FDA-Cleared COVID-19 Expanded Access Program, Enabling Patient Treatment Outside of Clinical Trial

NEXT STORY
Ventilator Market to Reach USD 9.13 Billion by 2027; Surging Number of Critical Cases Owing to COVID-19 will Boost Growth, says Fortune Business Insights™
PREV STORY
Biomaterials Market Worth USD 245.6 Billion at 12.2% CAGR; Increasing Number of Novel Product Launches to Skyrocket Demand: Fortune Business Insights™
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL

Overall response rate was 52% and median duration of response was not reached at ...

author_avatar
NASDAQ Market News

Kura Oncology to Participate in Piper Jaffray Healthcare Conference

author_avatar
NASDAQ Market News

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

author_avatar
NASDAQ Market News